Comparison · NCT05740566-sae
Tarlatamab 1 mg to 10 mg Q2W vs Standard of Care (SOC): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Tarlatamab 1 mg to 10 mg Q2W vs Standard of Care (SOC): serious adverse events. Trial comparisons, record NCT05740566-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05740566-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.512 | 0.45 | 0.573 | wilson | |
| Risk in group 2 | 0.512 | 0.45 | 0.574 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00039 | -0.0877 | 0.0869 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.999 | 0.841 | 1.19 | log | |
| Odds ratio, group 1 over group 2 | 0.998 | 0.702 | 1.42 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Tarlatamab 1 mg to 10 mg Q2W than on Standard of Care (SOC) | 2,560 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: standard of care.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Tarlatamab 1 mg to 10 mg Q2W | Participants were randomized to receive tarlatamab as an IV infusion: A step dose of 1 mg on Cycle 1 Day 1 followed by the target dose 10 mg on Cycle 1 Day 8, Cycle 1 Day 15, and Q2W thereafter. | 129 | 252 | EG001 |
| Group 2 | Standard of Care (SOC) | Participants were randomized to receive treatment according to the local SOC chemotherapy (lurbinectedin, topotecan, or amrubicin \[Japan only\]) in 21-day cycles. | 125 | 244 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
All-cause mortality: from randomization up to primary completion DCO date 29 January 2025; median (min, max) time was 8.6 (0.1, 18.5) months. Adverse events were collected from first dose of drug up to last dose + 65 days up to primary completion DCO date 29 January 2025; median (min, max) time was 5.3 (0.1, 17.3) months.
Source ClinicalTrials.gov
Trial
- Title
- Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
- NCT number
- NCT05740566
- Phases
- PHASE3
- Conditions
- Small Cell Lung Cancer (SCLC)
- Interventions
- Tarlatamab, Lurbinectedin, Topotecan, Amrubicin
- Lead sponsor
- Amgen
- Results first posted
- 2026-01-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05740566?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05740566-sae